Aptitude has been featured on Nature! https://lnkd.in/gbjGb4pS The tension between the at-home market and the healthcare provider market is real. On the other hand, every customer wants a product that is high-performance, rapid, and low-cost - these are the directions we keep working on. Our upcoming COVID/flu combo will have a 20-minute TAT, and our $50 reader enables everyone to start testing with minimal upfront cost. There is more to come.
Aptitude Medical Systems’ Post
More Relevant Posts
-
Aptitude's R&D team is expanding and we're #hiring! Are you someone who isn't afraid to challenge the status quo and believes in pushing boundaries and making a difference? Join us on our mission to democratize diagnostics! More open positions here: https://lnkd.in/gnsPpVC5
This content isn’t available here
Access this content and more in the LinkedIn app
-
Aptitude Receives Funding to Develop Tests for Sexually Transmitted Infections https://lnkd.in/gYwZxcHK
Aptitude Receives Funding to Develop Tests for Sexually Transmitted Infections
prnewswire.com
-
Join us at Booth #1468 at #2023AACC, and see how Aptitude is enabling decentralized molecular diagnostics! Our Metrix™ platform yields a result in 15–30 minutes, requires no calibration or maintenance, and has the lowest-cost instrument to enable effortless throughput scale-up without capital investment. The first test on our menu is the ONLY FDA EUA dual-sample (saliva+swab) COVID-19 test currently available in the US. We received significant funding in 2023 from BARDA, Gates Foundation, and NIH to develop a diverse test menu. We look forward to talking to you about our pipeline of products and how they may serve your testing needs.
Aptitude Medical Systems at the AACC Annual Scientific Meeting & Clinical Lab Expo
l.feathr.co